Is Charles River Laboratories (CRL) overvalued? · rev $2.00B
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
This page asks whether Charles River Laboratories (CRL) looks expensive on cached numbers — not a short thesis.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
CRL currently screens at market cap $7.78B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRL stock page for the full model, not this heading.
Not investment advice.